These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 25816404)

  • 21. CtBP1 is involved in epithelial-mesenchymal transition and is a potential therapeutic target for hepatocellular carcinoma.
    Zhang XL; Huang CX; Zhang J; Inoue A; Zeng SE; Xiao SJ
    Oncol Rep; 2013 Aug; 30(2):809-14. PubMed ID: 23756565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
    Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
    Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
    Yu M; Han G; Qi B; Wu X
    Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. POU2F1 over-expression correlates with poor prognoses and promotes cell growth and epithelial-to-mesenchymal transition in hepatocellular carcinoma.
    Zhong Y; Huang H; Chen M; Huang J; Wu Q; Yan GR; Chen D
    Oncotarget; 2017 Jul; 8(27):44082-44095. PubMed ID: 28489585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PNMA1, regulated by miR-33a-5p, promotes proliferation and EMT in hepatocellular carcinoma by activating the Wnt/β-catenin pathway.
    Liu P; Chen B; Gu Y; Liu Q
    Biomed Pharmacother; 2018 Dec; 108():492-499. PubMed ID: 30243081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells.
    Yu MM; Feng YH; Zheng L; Zhang J; Luo GH
    World J Gastroenterol; 2019 Mar; 25(10):1210-1223. PubMed ID: 30886504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proline-rich protein 11 silencing inhibits hepatocellular carcinoma growth and epithelial-mesenchymal transition through β-catenin signaling.
    Qiao W; Wang H; Zhang X; Luo K
    Gene; 2019 Jan; 681():7-14. PubMed ID: 30248355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma.
    Fan P; Wang B; Meng Z; Zhao J; Jin X
    Int J Biochem Cell Biol; 2018 Nov; 104():1-8. PubMed ID: 30172011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition.
    Pan Y; Wang B; Yang X; Bai F; Xu Q; Li X; Gao L; Ma C; Liang X
    Sci Rep; 2015 Nov; 5():17006. PubMed ID: 26593394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma.
    Xia H; Chen J; Shi M; Gao H; Sekar K; Seshachalam VP; Ooi LL; Hui KM
    J Hepatol; 2015 Oct; 63(4):863-73. PubMed ID: 25980764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.
    Zhan H; Jiang J; Luo C; Sun Q; Ke A; Sun C; Hu J; Hu Z; Hu B; Zhu K; Fan J; Zhou J; Huang X
    Tumour Biol; 2016 Jul; 37(7):9691-8. PubMed ID: 26801674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malic enzyme 1 induces epithelial-mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma.
    Wen D; Liu D; Tang J; Dong L; Liu Y; Tao Z; Wan J; Gao D; Wang L; Sun H; Fan J; Wu W
    Tumour Biol; 2015 Aug; 36(8):6211-21. PubMed ID: 25753478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma.
    Xiao H; Jiang N; Zhou B; Liu Q; Du C
    Cancer Sci; 2015 Feb; 106(2):151-9. PubMed ID: 25495189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
    Du R; Wu S; Lv X; Fang H; Wu S; Kang J
    J Exp Clin Cancer Res; 2014 Dec; 33(1):105. PubMed ID: 25499255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma.
    Asano T; Yamada S; Fuchs BC; Takami H; Hayashi M; Sugimoto H; Fujii T; Tanabe KK; Kodera Y
    Int J Oncol; 2017 May; 50(5):1647-1654. PubMed ID: 28350091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Li Y; Chen X; Lu H
    Oncol Res; 2016 Oct; 24(6):511-519. PubMed ID: 28281971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1.
    Li T; Li M; Hu S; Cheng X; Gao Y; Jiang S; Yu Q; Zhang C; Sun P; Xian W; Song Z; Zhang Y; Zheng Q
    Int J Biol Macromol; 2017 Oct; 103():1054-1061. PubMed ID: 28539268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma.
    Zhang W; Sun H; Shi X; Wang H; Cui C; Xiao F; Wu C; Guo X; Wang L
    Tumour Biol; 2016 Jun; 37(6):7741-8. PubMed ID: 26695141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma.
    Liu X; Huang Y; Jiang C; Ou H; Guo B; Liao H; Li X; Yang D
    Dig Liver Dis; 2016 Aug; 48(8):953-60. PubMed ID: 27257051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.